Risedronic acid

Generic Name: Risedronic acid

Brand Names: Actonel, Atelvia

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₁NO_₇P_₂

CAS Number: 105462-24-6

Unique Ingredient Identifier: KM2Z91756Z

Background: Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.

Indication: Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.

Associated Conditions: Hypercalcemia of Malignancy, Osteoporosis, Paget’s Disease

Associated Therapies: -

Clinical Trials

Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: Teriparatide
Drug: Risedronate

First Posted Date: 2007-07-18

Last Posted Date: 2012-03-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 92

Registration Number: NCT00503399

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

Phase 4

Completed

Conditions: Bone Loss
Osteoporosis
Breast Cancer

Interventions: Drug: risedronate

First Posted Date: 2007-06-13

Last Posted Date: 2017-10-13

Lead Sponsor: Susan L. Greenspan

Target Recruit Count: 109

Registration Number: NCT00485953

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.

Phase 4

Completed

Conditions: Colles' Fracture

Interventions: Drug: Calcium & Vitamine D3
Drug: Risedronate sodium

First Posted Date: 2007-04-16

Last Posted Date: 2011-10-04

Lead Sponsor: Sanofi

Target Recruit Count: 141

Registration Number: NCT00460733

Locations: 🇧🇷
Sanofi-Aventis Administrative Office, Sao Paulo, Brazil

Risedronate Sodium in Post Menopausal Osteoporosis

Phase 4

Completed

Conditions: Osteoporosis, Postmenopausal

First Posted Date: 2007-03-29

Last Posted Date: 2008-03-11

Lead Sponsor: Sanofi

Target Recruit Count: 246

Registration Number: NCT00453492

Locations: 🇹🇷
Sanofi-Aventis, Istanbul, Turkey

Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone

Phase 2

Completed

Conditions: Fibrous Dysplasia of Bone

Interventions: Drug: placebo
Drug: risedronate

First Posted Date: 2007-03-09

Last Posted Date: 2021-08-30

Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Target Recruit Count: 80

Registration Number: NCT00445575

Locations: 🇧🇪
Cliniques Universitaires Saint Luc, Brussels, Belgium
🇳🇱
Leids Universitair Medisch Centrum, Leiden, Netherlands
🇫🇷
Hopital E Herriot, Lyon, France

and more 5 locations

Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Control
Drug: risedronate

First Posted Date: 2007-01-25

Last Posted Date: 2012-02-03

Lead Sponsor: CMX Research

Target Recruit Count: 160

Registration Number: NCT00426777

Locations: 🇨🇦
Dr. Cal Andreou, Surrey, British Columbia, Canada
🇨🇦
Dr. Allan Patrick, Fredericton, New Brunswick, Canada
🇨🇦
Urology South Shore Research, Greenfield Park, Quebec, Canada

and more 18 locations

Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method

Phase 3

Completed

Conditions: Osteopenia

Interventions: Drug: Placebo comparator
Drug: risedronate

First Posted Date: 2006-10-11

Last Posted Date: 2012-01-11

Lead Sponsor: Warner Chilcott

Target Recruit Count: 161

Registration Number: NCT00386360

Locations: 🇬🇧
Research Facility, Cambridge, United Kingdom

A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.

Phase 4

Completed

Conditions: Post Menopausal Osteoporosis

Interventions: Drug: ibandronate [Bonviva/Boniva]
Drug: Risedronate

First Posted Date: 2006-09-18

Last Posted Date: 2016-08-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 356

Registration Number: NCT00377234

The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment

Phase 4

Completed

Conditions: Osteoporosis

First Posted Date: 2006-09-06

Last Posted Date: 2007-09-28

Lead Sponsor: Tuen Mun Hospital

Target Recruit Count: 120

Registration Number: NCT00372372

Locations: 🇨🇳
Tuen Mun Hospital, Hong Kong, China

Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: Parathyroid Hormone (PTH)
Drug: Risedronate

First Posted Date: 2006-08-17

Last Posted Date: 2012-08-20

Lead Sponsor: Takeda

Target Recruit Count: 407

Registration Number: NCT00365456

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy